Dec 10, 2024 · Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and validate new therapeutic targets for osteoarthritis and fibrotic diseases.

Jan 30, 2025 · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations

Oct 8, 2024 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first proposed by the US government late last year due to concerns about national security and how genetic and other biological data could be misused by foreign adversarial governments with a focus on China.

Nov 26, 2024 · The exact prevalence of ATTR-CM is uncertain but is thought to be higher than previously thought. Estimates have increased from 5 in 100,000 people in 2004 to 35 per 100,000 people in 2022.

Jun 6, 2024 · Nucleus RadioPharma, a leading player in the development, manufacturing, and supply chain management of radiopharmaceuticals, has announced a significant milestone with the closing of a Series A extension round, featuring a new investment from AstraZeneca.

May 15, 2024 · Daniel Spurgin, director of strategic partnerships at ReciBioPharm, unveiled the company's BIO 2024 plans and how the CDMO is set to flourish as more viral and nucleic acid therapeutics move to the clinic in the next two years.

Dec 12, 2024 · Chroma Bio was launched in 2021 with $125 million in seed funding and aimed to take gene editing one step further by editing the epigenome, namely, markers on the genome that control the way genes are expressed in response to different stimuli.. Nvelop began in stealth mode in 2022, but officially launched earlier this year with $100 million in funding.

Oct 29, 2024 · UK-based private biotech company Ottimo Pharma has emerged from stealth mode after four years with the appointment of a strong leadership team.

May 13, 2024 · The therapy has sparked significant anticipation within the medical community ahead of its phase 3 outcomes. A positive outcome from this study could lay the groundwork for regulatory approval, potentially reshaping the treatment landscape for bronchiectasis, a condition currently without any globally approved therapies.

Aug 8, 2024 · Falko Busse, president of Bruker BioSpin. bring together NovAliX, Bruker, and the renowned Max Planck Institute. This collaborative environment is set to provide scientists from both academia and industry with access to state-of-the-art biophysics instrumentation and drug discovery expertise, fostering the development of next-generation therapeutic technologies.